Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biogen Idec Limited
Woman Max 99 years
Biogen Idec Limited
Update Il y a 5 ans
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
To evaluate the efficacy of volociximab when administered at 15 mg/kg per week in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Limited
Update Il y a 5 ans
A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB017 in subjects originally treated in Study 105MS301 who continue BIIB017 treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Limited
Update Il y a 5 ans
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Part 1: The primary objective of the study is to investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in subjects with SPMS. Part 2: The pri...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Limited
Update Il y a 5 ans
A Study to Evaluate the Effect of Different Doses of TYSABRI on Safety and Efficacy in Relapsing Multiple Sclerosis
To explore the effects of multiple regimens of natalizumab on disease activity and safety in subjects with relapsing remitting MS.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Limited
Update Il y a 5 ans
Study to Evaluate BIIB019, Daclizumab High Yield Process (DAC HYP), when administered by Pre-filled Syringe
The primary objective of the study is to assess the immunogenicity of DAC HYP 150 mg administered every 4 weeks by an SC injection using the pre-filled syringe (PFS) in subjects with RRMS.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Limited
Update Il y a 5 ans
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BG00012 when given with Methotrexate to Subjects with Active Rheumatoid Arthritis who have had an Inadequate Response to Coventional Disease-Modifying Anti-rheumatic Drug Therapy
The primary objective of this study is to evaluate the clinical efficacy of BG00012 with MTX in subjects with active RA who have had an inadequate response to DMARD therapy.
Country
None
organs
None
Specialty
None
Closed trial
More information